ORIC Pharmaceuticals (ORIC)

Executive Summary

ORIC Pharmaceuticals is a clinical-stage oncology company dedicated to developing novel therapeutics that overcome resistance mechanisms in cancer, thereby making existing therapies more effective and durable. Founded in 2014 and headquartered in South San Francisco, the company focuses on targeting innate, acquired, and bypass resistance across multiple tumor types. ORIC's pipeline includes several small molecule candidates, with its lead program, ORIC-944, a PRMT5 inhibitor, advancing in Phase 1/2 trials for solid tumors, particularly prostate cancer. The company also has early-stage programs targeting EGFR exon 20 insertions and CD73. With a strong scientific foundation in resistance biology and a management team experienced in drug development, ORIC aims to address significant unmet needs in oncology. The company went public and maintains a robust balance sheet to support its clinical programs through key data readouts. ORIC is approaching several important milestones that could drive value. The most significant near-term catalyst is the expected Phase 1/2 data for ORIC-944 in patients with advanced solid tumors, which will provide initial proof-of-concept for its mechanism of action. Additionally, the company may initiate a Phase 2 expansion cohort in prostate cancer following encouraging early signals. Beyond ORIC-944, updates on preclinical and early clinical programs, such as ORIC-114 (EGFR exon 20 inhibitor) and ORIC-533 (CD73 inhibitor), could further validate the platform. Successful data readouts would de-risk the pipeline and potentially support partnership or regulatory discussions. However, clinical-stage biotech investments carry inherent risk, including potential for disappointing results, competitive landscape, and financing needs.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 data readout for ORIC-944 in solid tumors60% success
• Q4 2026Initiation of Phase 2 expansion cohort for ORIC-944 in prostate cancer70% success
• Q2 2026Preclinical/early clinical updates for ORIC-114 or ORIC-53375% success